Want to see JP:4894 full AI Analyst Report?
Top Page
Cuorips Inc.
(4894)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥6,252.00
▲(0.35% Upside)
Action:Reiterated
Date:10/02/26
The score is held back primarily by weak operating performance (declining revenue, widening losses) and worsening cash burn, partially offset by a strong, low-risk balance sheet with zero debt and sizable equity. Technically, the stock shows positive trend/momentum but appears somewhat overextended, while valuation support is limited due to losses and no dividend yield data.
Positive Factors
Debt-free balance sheet
A debt-free capital structure reduces mandatory interest and refinancing obligations, giving Cuorips greater flexibility while it funds development. This lowers balance-sheet risk and provides more time to pursue commercialization or operational improvements without immediate leverage pressure.
Negative Factors
Latest revenue decline
The latest annual revenue contraction signals weakening commercial momentum and makes future scale harder to achieve. Prolonged sales declines could reduce operating leverage, limit reinvestment capacity, and increase the time required for the company to convert its business into sustainable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure reduces mandatory interest and refinancing obligations, giving Cuorips greater flexibility while it funds development. This lowers balance-sheet risk and provides more time to pursue commercialization or operational improvements without immediate leverage pressure.
Read all positive factors
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥55.59B
Dividend YieldN/A
Average Volume (3M)94.60K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth-50.60%
EPS Growth-70.48%
CountryJP
Employees51
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-138.34
Shares Outstanding8,896,416
10 Day Avg. Volume104,410
30 Day Avg. Volume94,603
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)12.12
Price to Sales (P/S)271.07
P/FCF Ratio-52.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cuorips Inc. Business Overview & Revenue Model
Company Description
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-ba...
Cuorips Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 128.59M | 212.33M | 175.21M | 23.10M | 38.28M | 13.91M |
| Gross Profit | 5.13M | 45.90M | 91.56M | -60.47M | -57.64M | -82.09M |
| EBITDA | -1.12B | -996.81M | -513.57M | -518.38M | -371.78M | -280.46M |
| Net Income | -1.14B | -1.02B | -644.34M | -632.18M | -452.08M | -375.34M |
Balance Sheet | ||||||
| Total Assets | 4.81B | 5.12B | 5.74B | 6.18B | 3.59B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.32B | 3.90B | 4.79B | 5.58B | 2.94B | 3.34B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 354.46M | 353.83M | 211.91M | 200.96M | 133.79M | 149.36M |
| Stockholders Equity | 4.44B | 4.75B | 5.53B | 5.98B | 3.45B | 3.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.10B | -892.81M | -474.83M | -412.18M | -249.45M |
| Operating Cash Flow | 0.00 | -1.06B | -812.62M | -451.06M | -401.61M | -220.76M |
| Investing Cash Flow | 0.00 | -7.59M | -117.99M | -33.50M | -8.97M | -28.44M |
| Financing Cash Flow | 0.00 | 176.84M | 143.11M | 3.12B | 10.69M | 48.54M |
Cuorips Inc. Technical Analysis
Positive
6230.00
Price Trends
5277.20
Positive
4963.55
Positive
6116.02
Positive
Market Momentum
246.66
Negative
60.73
Neutral
68.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6230 is above the 20-day moving average (MA) of 5691.00, above the 50-day MA of 5277.20, and above the 200-day MA of 6116.02, indicating a bullish trend. The MACD of 246.66 indicates Negative momentum. The RSI at 60.73 is Neutral, neither overbought nor oversold. The STOCH value of 68.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.
Cuorips Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ¥55.59B | -45.25 | ― | ― | -50.60% | -70.48% | |
47 Neutral | ¥38.90B | 57.86 | ― | ― | -47.32% | ― | |
46 Neutral | ¥33.83B | -76.85 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥13.72B | -28.76 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.50B | -7.42 | ― | ― | -56.16% | 3.12% | |
40 Underperform | ¥10.28B | -5.52 | ― | ― | ― | 4.68% |
* General Sector Average
JP:4894
Cuorips Inc.
6,260.00
-1,030.00
-14.13%
JP:4593
Healios KK
287.00
-222.00
-43.61%
JP:4599
StemRIM Inc.
164.00
-127.00
-43.64%
JP:4978
ReproCELL Inc.
132.00
-58.00
-30.53%
JP:7774
Japan Tissue Engineering Co., Ltd.
833.00
333.00
66.60%
JP:7776
CellSeed Inc.
215.00
-219.00
-50.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.